Euroapi Company Header Euroapi Company Header

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu

    Find the latest news about Gilead Sciences aggregated by PharmaCompass.com.

    Client Virtual Booth

    GILEAD SCIENCES

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    APIs // Active Pharmaceutical Ingredients

    DEVELOPMENTS

    DOSSIERs // Finished Dosage Formulations

    EXCIPIENTS

    INSPECTIONS & REGISTRATIONS

    PharmaCompass
    Contact SupplierContact Supplier
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Send me more info on How To Grow My Bussiness Digitally?
    Gilead Sciences
    United_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    333 Lakeside Drive Foster City, CA 94404
    Telephone
    Telephone
    +1 650 574 3000
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.gilead.com/
    Linkedin
    Linkedin
    https://www.linkedin.com/company/gilead-sciences/
    Twitter
    Twitter
    https://twitter.com/GileadSciences

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Full View ScreenFull Screen View
    Chief Medical Officer Merdad Parsey to Leave Gilead Early 2025
    Chief Medical Officer Merdad Parsey to Leave Gilead Early 2025

    https://www.businesswire.com/news/home/20240716867026/en

    BUSINESSWIRE
    17 Jul 2024
    Share Share
    US government appeals Gilead's trial win in Truvada, Descovy patent fight
    US government appeals Gilead's trial win in Truvada, Descovy patent fight

    https://www.fiercepharma.com/pharma/gilead-faces-prep-threat-after-us-appeals-trial-win-truvada-and-descovy-patent-litigation

    FIERCE PHARMA
    09 Jul 2024
    Share Share
    Gilead Benefit Helps Employees Navigate Cancer Care
    Gilead Benefit Helps Employees Navigate Cancer Care

    https://www.accesswire.com/viewarticle.aspx?id=883848&lang=en

    ACCESSWIRE
    01 Jul 2024
    Share Share
    After Gilead and J&J lawsuits, distributor Safe Chain sees its owners charged
    After Gilead and J&J lawsuits, distributor Safe Chain sees its owners charged

    https://www.fiercepharma.com/pharma/counterfeit-hiv-med-crackdown-continues-us-indictment-targeting-owners-distributor-safe

    FIERCE PHARMA
    01 Jul 2024
    Share Share
    Hookipa Doses First Person In HB-500 HIV Treatment Trial
    Hookipa Doses First Person In HB-500 HIV Treatment Trial

    https://www.globenewswire.com/news-release/2024/07/01/2907081/0/en/HOOKIPA-Pharma-Announces-First-Person-Dosed-in-Phase-1b-Clinical-Trial-of-HB-500-for-the-Treatment-of-HIV.html

    GLOBENEWSWIRE
    01 Jul 2024
    Share Share
    Kite Pharma to Evaluate Cellares’ Automated Manufacturing Platform
    Kite Pharma to Evaluate Cellares’ Automated Manufacturing Platform

    https://www.contractpharma.com/contents/view_breaking-news/2024-06-27/kite-pharma-to-evaluate-cellares-automated-manufacturing-platform/

    CONTRACT PHARMA
    28 Jun 2024
    Share Share
    Gilead's Kite signs on with Cellares for cell therapy manufacturing test
    Gilead's Kite signs on with Cellares for cell therapy manufacturing test

    https://www.fiercepharma.com/manufacturing/gileads-kite-signs-cellares-cell-therapy-manufacturing-test

    FIERCE PHARMA
    27 Jun 2024
    Share Share
    Gilead's long-acting HIV drug superior to daily pill Truvada in study
    Gilead's long-acting HIV drug superior to daily pill Truvada in study

    https://www.reuters.com/business/healthcare-pharmaceuticals/gileads-long-acting-hiv-drug-superior-daily-pill-truvada-study-2024-06-20/

    Mariam E Sunny REUTERS
    21 Jun 2024
    Share Share
    Gilead And Kite Pharma Celebrate Pride Month
    Gilead And Kite Pharma Celebrate Pride Month

    https://www.accesswire.com/viewarticle.aspx?id=879148&lang=en

    ACCESSWIRE
    19 Jun 2024
    Share Share
    EU regulator requires secondary cancer risk warning for CAR-T therapies
    EU regulator requires secondary cancer risk warning for CAR-T therapies

    https://www.reuters.com/business/healthcare-pharmaceuticals/eu-regulator-mandates-label-updates-car-t-cancer-therapies-2024-06-14/

    REUTERS
    15 Jun 2024
    Share Share
    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    famar-2024-07-22

    Access Virtual Booth

    Contact Supplier

    Send me more info on How To Grow My Business Digitally?
    Post Enquiry
    POST ENQUIRY

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search